Sotorasib for lung cancer
Technical Data for sotorasib
| M. Wt | 560.61 |
| Formula | C30H30F2N6O3 |
| Storage | Store at +4°C |
| Purity | ≥99% (HPLC) |
| CAS Number | 2296729-00-3 |
| Other name | AGM-510,AMG-510 racemate,2252403-56-6,AMG510,AMG 510 |
| Synoym | AMG-510 racemate,2252403-56-6,4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one |
| Smiles | O=C(C=C)N1C[C@H](C)N(C2=NC(N(C3=C(C)C=CN=C3C(C)C)C4=C2C=C(F)C(C5=C(O)C=CC=C5F)=N4)=O)CC1. |
What is sotorasib made from?
Sotorasib, also known as AMG-510, is an acrylamide derived KRAS inhibitor developed by Amgen. It is indicated in the treatment of adult patients with KRAS G12C mutant non small cell lung cancer. This mutation makes up >50% of all KRAS mutations.
What is sotorasib used for?
Under the new approval On May 28, 2021, sotorasib (Lumakras, Amgen)) can be used to treat Adults with non-small cell lung cancer (NSCLC) that has spread nearby (locally advanced) or to distant locations (metastatic) in the body.
How effective is sotorasib?
In the clinical trial, called CodeBreaK100, sotorasib achieved a 37.1% objective response rate and a median overall survival of 12.5 months